Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Growth 2026-2032
The global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Monoclonal antibody anti-VEGF ophthalmic drugs are a class of medications specifically engineered to target and neutralize vascular endothelial growth factor(VEGF),a key protein involved in angiogenesis and vascular permeability in the eye.These drugs are administered via intravitreal injection directly into the eye to treat diseases like wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema.
United States market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Monoclonal Antibody Anti-VEGF Ophthalmic Drugs players cover Roche, Novartis, Coherus BioSciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Forecast? looks at past sales and reviews total world Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales for 2026 through 2032. With Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibody Anti-VEGF Ophthalmic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibody Anti-VEGF Ophthalmic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Monoclonal antibody anti-VEGF ophthalmic drugs are a class of medications specifically engineered to target and neutralize vascular endothelial growth factor(VEGF),a key protein involved in angiogenesis and vascular permeability in the eye.These drugs are administered via intravitreal injection directly into the eye to treat diseases like wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema.
United States market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Monoclonal Antibody Anti-VEGF Ophthalmic Drugs players cover Roche, Novartis, Coherus BioSciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the ?Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Forecast? looks at past sales and reviews total world Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales for 2026 through 2032. With Monoclonal Antibody Anti-VEGF Ophthalmic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoclonal Antibody Anti-VEGF Ophthalmic Drugs industry.
This Insight Report provides a comprehensive analysis of the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Monoclonal Antibody Anti-VEGF Ophthalmic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Faricimab
- Brolucizumab
- Brolucizumab
- Other
- Age-related Macular Degeneration
- Diabetic Retinopathy
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Roche
- Novartis
- Coherus BioSciences
- What is the 10-year outlook for the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market?
- What factors are driving Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market opportunities vary by end market size?
- How does Monoclonal Antibody Anti-VEGF Ophthalmic Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Country/Region, 2021, 2025 & 2032
2.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Type
2.2.1 Faricimab
2.2.2 Brolucizumab
2.2.3 Brolucizumab
2.2.4 Other
2.2.5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type
2.2.5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Type (2021-2026)
2.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Application
2.3.1 Age-related Macular Degeneration
2.3.2 Diabetic Retinopathy
2.3.3 Other
2.3.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application
2.3.4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2021-2026)
2.3.4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Breakdown Data by Company
3.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2021-2026)
3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Company (2021-2026)
3.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Company
3.4 Key Manufacturers Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Location Distribution
3.4.2 Players Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
4.4 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
4.5 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
4.6 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
5 AMERICAS
5.1 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country
5.1.1 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026)
5.1.2 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026)
5.2 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
5.3 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region
6.1.1 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026)
6.1.2 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021-2026)
6.2 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
6.3 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Country
7.1.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026)
7.1.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026)
7.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
7.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Country
8.1.1 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
10.3 Manufacturing Process Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
10.4 Industry Chain Structure of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors
11.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customer
12 WORLD FORECAST REVIEW FOR MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
12.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Forecast by Region
12.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Forecast by Region (2027-2032)
12.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Forecast by Type (2027-2032)
12.7 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.1.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.2.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Coherus BioSciences
13.3.1 Coherus BioSciences Company Information
13.3.2 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.3.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Coherus BioSciences Main Business Overview
13.3.5 Coherus BioSciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Country/Region, 2021, 2025 & 2032
2.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Type
2.2.1 Faricimab
2.2.2 Brolucizumab
2.2.3 Brolucizumab
2.2.4 Other
2.2.5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type
2.2.5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
2.2.5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Type (2021-2026)
2.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Segment by Application
2.3.1 Age-related Macular Degeneration
2.3.2 Diabetic Retinopathy
2.3.3 Other
2.3.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application
2.3.4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2021-2026)
2.3.4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Breakdown Data by Company
3.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2021-2026)
3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Company (2021-2026)
3.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Company
3.4 Key Manufacturers Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Location Distribution
3.4.2 Players Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
4.4 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
4.5 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
4.6 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth
5 AMERICAS
5.1 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country
5.1.1 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026)
5.1.2 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026)
5.2 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
5.3 Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region
6.1.1 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026)
6.1.2 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021-2026)
6.2 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
6.3 APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Country
7.1.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026)
7.1.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026)
7.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
7.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Country
8.1.1 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
10.3 Manufacturing Process Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
10.4 Industry Chain Structure of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors
11.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customer
12 WORLD FORECAST REVIEW FOR MONOCLONAL ANTIBODY ANTI-VEGF OPHTHALMIC DRUGS BY GEOGRAPHIC REGION
12.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Forecast by Region
12.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Forecast by Region (2027-2032)
12.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Forecast by Type (2027-2032)
12.7 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Roche
13.1.1 Roche Company Information
13.1.2 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.1.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Roche Main Business Overview
13.1.5 Roche Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.2.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Coherus BioSciences
13.3.1 Coherus BioSciences Company Information
13.3.2 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
13.3.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Coherus BioSciences Main Business Overview
13.3.5 Coherus BioSciences Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Faricimab
Table 4. Major Players of Brolucizumab
Table 5. Major Players of Brolucizumab
Table 6. Major Players of Other
Table 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Table 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale by Application (2021-2026) & (K Units)
Table 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2021-2026)
Table 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & ($ million)
Table 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021-2026)
Table 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Company (2021-2026) & (K Units)
Table 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2021-2026)
Table 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2021-2026)
Table 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Producing Area Distribution and Sales Area
Table 23. Players Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Products Offered
Table 24. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share Geographic Region (2021-2026)
Table 29. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2021-2026)
Table 33. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units)
Table 36. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021-2026)
Table 37. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 39. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 40. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026) & (K Units)
Table 41. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021-2026)
Table 42. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 44. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 45. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units)
Table 46. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 48. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Table 54. Key Market Challenges & Risks of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Table 55. Key Industry Trends of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Table 56. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors List
Table 59. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customer List
Table 60. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Roche Basic Information, Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 75. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 76. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Roche Main Business
Table 78. Roche Latest Developments
Table 79. Novartis Basic Information, Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 81. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Novartis Main Business
Table 83. Novartis Latest Developments
Table 84. Coherus BioSciences Basic Information, Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 86. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Coherus BioSciences Main Business
Table 88. Coherus BioSciences Latest Developments
Table 1. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Faricimab
Table 4. Major Players of Brolucizumab
Table 5. Major Players of Brolucizumab
Table 6. Major Players of Other
Table 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Table 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2021-2026) & ($ million)
Table 10. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2026)
Table 11. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale by Application (2021-2026) & (K Units)
Table 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2021-2026)
Table 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2021-2026) & ($ million)
Table 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021-2026)
Table 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Company (2021-2026) & (K Units)
Table 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Company (2021-2026)
Table 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company (2021-2026)
Table 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Producing Area Distribution and Sales Area
Table 23. Players Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Products Offered
Table 24. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share Geographic Region (2021-2026)
Table 29. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2021-2026)
Table 33. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units)
Table 36. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021-2026)
Table 37. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 39. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 40. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2021-2026) & (K Units)
Table 41. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021-2026)
Table 42. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 44. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 45. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units)
Table 46. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 48. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Table 54. Key Market Challenges & Risks of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Table 55. Key Industry Trends of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Table 56. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors List
Table 59. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customer List
Table 60. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Roche Basic Information, Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 75. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 76. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Roche Main Business
Table 78. Roche Latest Developments
Table 79. Novartis Basic Information, Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 80. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 81. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. Novartis Main Business
Table 83. Novartis Latest Developments
Table 84. Coherus BioSciences Basic Information, Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 85. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolios and Specifications
Table 86. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Coherus BioSciences Main Business
Table 88. Coherus BioSciences Latest Developments
LIST OF FIGURES
Figure 1. Picture of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 2. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2025)
Figure 10. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Faricimab
Figure 12. Product Picture of Brolucizumab
Figure 13. Product Picture of Brolucizumab
Figure 14. Product Picture of Other
Figure 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type in 2026
Figure 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumed in Age-related Macular Degeneration
Figure 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Age-related Macular Degeneration (2021-2026) & (K Units)
Figure 19. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumed in Diabetic Retinopathy
Figure 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Diabetic Retinopathy (2021-2026) & (K Units)
Figure 21. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumed in Other
Figure 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Other (2021-2026) & (K Units)
Figure 23. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2025)
Figure 24. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application in 2026
Figure 25. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Company in 2026 (K Units)
Figure 26. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Company in 2026
Figure 27. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Company in 2026 ($ millions)
Figure 28. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company in 2026
Figure 29. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 32. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 33. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 34. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 35. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 36. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 39. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2026
Figure 40. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021-2026)
Figure 41. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 42. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 43. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region in 2026
Figure 48. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021-2026)
Figure 49. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 50. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 51. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2026
Figure 59. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021-2026)
Figure 60. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 61. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 62. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 70. Egypt Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in 2026
Figure 76. Manufacturing Process Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 77. Industry Chain Structure of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 78. Channels of Distribution
Figure 79. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Forecast by Region (2027-2032)
Figure 80. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 2. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2025)
Figure 10. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Faricimab
Figure 12. Product Picture of Brolucizumab
Figure 13. Product Picture of Brolucizumab
Figure 14. Product Picture of Other
Figure 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type in 2026
Figure 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021-2026)
Figure 17. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumed in Age-related Macular Degeneration
Figure 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Age-related Macular Degeneration (2021-2026) & (K Units)
Figure 19. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumed in Diabetic Retinopathy
Figure 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Diabetic Retinopathy (2021-2026) & (K Units)
Figure 21. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Consumed in Other
Figure 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market: Other (2021-2026) & (K Units)
Figure 23. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sale Market Share by Application (2025)
Figure 24. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application in 2026
Figure 25. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Company in 2026 (K Units)
Figure 26. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Company in 2026
Figure 27. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Company in 2026 ($ millions)
Figure 28. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Company in 2026
Figure 29. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Geographic Region in 2026
Figure 31. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 32. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 33. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 34. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 35. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 36. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2021-2026 ($ millions)
Figure 39. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2026
Figure 40. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021-2026)
Figure 41. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 42. Americas Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 43. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region in 2026
Figure 48. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021-2026)
Figure 49. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 50. APAC Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 51. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country in 2026
Figure 59. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021-2026)
Figure 60. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 61. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 62. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. UK Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021-2026)
Figure 70. Egypt Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in 2026
Figure 76. Manufacturing Process Analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 77. Industry Chain Structure of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 78. Channels of Distribution
Figure 79. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Forecast by Region (2027-2032)
Figure 80. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share Forecast by Application (2027-2032)
